Flexible pricing could work in Europe
This article was originally published in Scrip
GlaxoSmithKline recently published its corporate responsibility report, which shone a spotlight on a pricing system that promotes access to affordable medicines, whilst ensuring a healthy return for reinvestment in R&D. The flexible pricing mechanism has been employed successfully by the company to increase access to medicines in middle income countries (MICs), such as Brazil, China, Thailand, India and Indonesia. The question many are asking is whether such a system could be brought to Europe and if so, would it be valuable?